Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) is now available.
Recordati S.p.A. has completed its share buyback program, initiated on April 30, 2025, as per the resolution of the Shareholders’ Meeting. The program aimed to purchase shares to service stock options and performance share plans for the management of the Recordati Group. Between April 30 and October 24, 2025, Recordati purchased a total of 2,000,000 shares, representing 0.956% of its share capital, at an average price of €52.3656. As of October 24, 2025, the company held 4,728,240 own shares, equating to 2.261% of the share capital. This strategic move is expected to support the company’s incentive plans and potentially enhance shareholder value.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR55.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati is an international pharmaceutical group listed on the Italian Stock Exchange, originating from a family-run pharmacy in Northern Italy in the 1920s. The company offers therapeutic options in both general and specialist medicine segments, as well as rare diseases. It operates in a fully integrated manner, covering clinical development, production, marketing, and licensing of active ingredients and finished products. Recordati is present in about 150 countries across the EMEA, Americas, and APAC regions, with over 4,580 employees worldwide.
YTD Price Performance: 3.62%
Average Trading Volume: 244,240
Technical Sentiment Signal: Buy
Current Market Cap: €10.68B
Find detailed analytics on REC stock on TipRanks’ Stock Analysis page.